Safety and Efficacy of LY3875383 in Healthy and Hypertriglyceridemia Participants

Phase 1, randomised, single-blind trial of LY3875383 in hypertriglyceridemia (8 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration. Started Nov 2022; status: terminated.